

1 **Evaluation of a SARS-CoV-2 rapid antigen test: potential to help reduce community**  
2 **spread?**

3 Tuna Toptan<sup>1,\*</sup>, Lisa Eckermann, Annika E. Pfeiffer<sup>1</sup>, Sebastian Hoehl<sup>1</sup>, Sandra Ciesek<sup>1</sup>, Christian  
4 Drosten<sup>2</sup>, Victor M. Corman<sup>2</sup>

5 1 Institute of Medical Virology, University Hospital Frankfurt am Main, Goethe University,  
6 Frankfurt am Main 60590 Germany

7 2 Charité – Universitätsmedizin Berlin Institute of Virology, Berlin, Germany and German  
8 Centre for Infection Research (DZIF), Berlin, Germany

9 **ABSTRACT**

10  
11 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can spread from symptomatic  
12 patients with COVID-19, but also from asymptomatic individuals. Therefore, robust surveillance  
13 and timely interventions are essential for the control of virus spread within the community. In this  
14 regard the frequency of testing and speed of reporting, but not the test sensitivity alone, play a  
15 crucial role. In order to reduce the costs and meet the expanding demands in real-time RT-PCR  
16 (rRT-PCR) testing for SARS-CoV-2, complementary assays, such as rapid antigen tests, have  
17 been developed. Rigorous analysis under varying conditions is required to assess the clinical  
18 performance of these tests and to ensure reproducible results. We evaluated the sensitivity and  
19 specificity of a recently licensed rapid antigen test using 137 clinical samples in two institutions.  
20 Test sensitivity was between 88.2-89.6% when applied to samples with viral loads typically seen  
21 in infectious patients. Of 32 rRT-PCR positive samples, 19 demonstrated infectivity in cell culture,  
22 and 84% of these samples were reactive with the antigen test. Seven full-genome sequenced  
23 SARS-CoV-2 isolates and SARS-CoV-1 were detected with this antigen test, with no cross-  
24 reactivity against other common respiratory viruses. Numerous antigen tests are available for  
25 SARS-CoV-2 testing and their performance to detect infectious individuals may vary. Head-to-

26 head comparison along with cell culture testing for infectivity may prove useful to identify better  
27 performing antigen tests. The antigen test analyzed in this study is easy-to-use, inexpensive, and  
28 scalable. It can be helpful in monitoring infection trends and thus has potential to reduce  
29 transmission.

30

## 31 1. INTRODUCTION

32 Since the beginning of COVID-19 outbreak in December 2020, the global demand for the  
33 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing has been steadily  
34 increasing. Already back in March 2020, hospitals and laboratories around the world announced  
35 their concerns about reagent, consumable material shortages, and limited personal protective  
36 equipment. Yet, timely detection and isolation of SARS-CoV-2 infected cases and identification of  
37 their contacts are pivotal to slowing down the pandemic.

38 The main public health strategy during a pandemic relies on robust and easy to perform  
39 diagnostic tools that can be used to test large number of samples in a short time. To date the gold  
40 standard diagnostic method for SARS-CoV-2 detection [1] is based on real time reverse  
41 transcription-PCR (rRT-PCR) technology which has been promptly implemented by the World  
42 Health Organization (WHO) [2], Center for Disease Control and Prevention (CDC) [3] protocols,  
43 and a number of commercial assays [4]. The SARS-CoV-2 rRT-PCR has high specificity and  
44 sensitivity [5, 6]. However, the type and quality of the patient specimen [7, 8], stage of the disease,  
45 and the degree of viral replication and/or clearance have an impact on the test outcome [9]. These  
46 factors are critical not only for PCR-based but also for other diagnostic test systems aiming to  
47 detect the presence of the virus. Hence interpreting a test result for SARS-CoV-2 depends on the  
48 accuracy of the test, but the prevalence and the estimated risk of disease before testing should  
49 also be taken into consideration.

50 In many countries SARS-CoV-2 testing is extended to asymptomatic population, e.g. in  
51 schools, airports, nursing-homes, and workplaces. This leads to a growing gap between the large  
52 number of demand and the laboratory capacities to perform rRT-PCR tests, especially in  
53 developing countries. Despite high specificity and sensitivity, rRT-PCR has a disadvantage in point  
54 of care testing, because it usually requires professional expertise, expensive reagents and  
55 specialized equipment. Therefore, alternative assays, such as rapid antigen detection tests, which

56 can also detect the presence of the virus directly in respiratory samples, have been developed [4]  
57 and tested by different groups [10-14]. However, it is vital to determine the sensitivity, specificity  
58 of such tests relative to standard rRT-PCR in order to identify the ideal circumstances that their  
59 application would be beneficial.

60 This study was performed to evaluate a novel antigen test produced by R-Biopharm for  
61 the detection of SARS-CoV-2 in different specimens and to identify its limitations and potential  
62 usage. Different types of materials and verification analysis were used by two institutions  
63 independently to assure the reproducibility of the testing and to analyze the potential caveats.

64

## 65 **2. MATERIALS AND METHODS**

### 66 *2.1 Specimen collection*

67 At the Institute of Virology, Charité Berlin stored specimens taken after routine diagnostic were  
68 used with no extra procedures required for the study. Cell culture supernatants of respiratory  
69 viruses other than SARS-CoV-2 were available at the institute of virology, Charite through a EVD-  
70 LabNet EQA (<https://www.evd-labnet.eu/>; Fischer/Mögling, unpublished data).

71 At the Institute of Virology, Frankfurt, the clinical samples were collected from subjects as part of  
72 registered protocols. Combined oropharyngeal/nasal swabs were collected, stored in 2 ml PBS at  
73 4°C and processed for further analysis within 24 hours.

74

### 75 *2.2 Cell culture and virus stocks*

76 Caco-2 (human colon carcinoma) were cultured in Minimum Essential Medium (MEM)  
77 supplemented with 10% fetal calf serum (FCS). 100 IU/mL of penicillin and 100 g/mL of  
78 streptomycin. All culture reagents were purchased from Sigma (St. Louis, MO, USA). The Caco-  
79 2 cells were originally obtained from DSMZ (Braunschweig, Germany, no.: ACC 169) differentiated  
80 by serial passaging and selected for high permissiveness to virus infection. Caco-2 cells were

81 infected with different viral isolates (FFM1-FFM7) [15] at an MOI 0.1. Cell culture supernatant was  
82 harvested 48 h after infection, precleared at 2000 x g for 10 min at room temperature. Aliquots of  
83 virus particle containing supernatant were kept at -80°C.

84

### 85 *2.3 Detection of infectious virus in cell culture*

86 Of the swab-dilution, 500 µL were mixed with 1.5 ml of MEM containing 1% FCS (Sigma-Aldrich;  
87 St. Louis, Missouri, USA), 7.5 µg/ml Amphotericin B, and 0.1 mg/ml Primocin, (InvivoGen; San  
88 Diego, California, USA). Swab-inoculums were transferred to Caco-2 cells seeded in 5.5 cm<sup>2</sup>  
89 culture tubes. Cytopathogenic effect (CPE) was assessed daily for up to seven days or until cell  
90 lysis occurred.

91

### 92 *2.4 Rapid Antigen Test*

93 Rapid antigen test was provided by R-Biopharm. Test was performed according to the  
94 manufacturer's recommendations and evaluated visually by four or six-eye principle. Briefly,  
95 samples were vortexed for 20 sec. 50 µl from Solution A (blue) and B (yellow) were dispensed in  
96 clean 1.5 ml reaction tubes which leads to green coloring. Immediately 50 µl of the test samples  
97 were added to the reaction mixture. Samples were then mixed briefly and incubated for 10 min at  
98 room temperature. Test strips were placed in to mixture vertically to allow absorption. Test results  
99 were evaluated after 10 min. Intensities of the test bands were compared to control band  
100 categorized as follows: +++ (test band intensity stronger than the control), ++ (test and control  
101 bands intensity are similar), + (test band intensity is weaker than the control). Antigen testing for  
102 viable SARS-CoV-2 and SARS-CoV-1 cell culture supernatants was performed in a BSL-3  
103 laboratory.

104

### 105 *2.5 RNA extraction and rRT-PCR analysis*

106 At the Institute of Virology, Charité Berlin, stored samples (swab resuspended in 1.5 mL of  
107 phosphate-buffered saline) were anonymized before testing. After thawing at RT all samples were  
108 analyzed by antigen test and rRT-PCR in parallel. RNA extraction for rRT-PCR was done by using  
109 the MagNA Pure 96 system, using 100 µl of sample, eluted in 100 µl. rRT-PCR was done as  
110 published previously [1].

111 At the Institute of Virology in Frankfurt the SARS-CoV-2 test (Cobas, Roche, Basel, Switzerland)  
112 was performed on the rRT-PCR automated Cobas 6800 system. Of the swab-dilution, 1000 µl  
113 aliquots were mixed with lysis buffer (1:1 ratio) and 500 µL aliquots were transferred to barcoded  
114 secondary tubes, loaded on the Cobas 6800 system, and tested with Cobas SARS-CoV-2 master  
115 mix containing an internal RNA control and primer-probe sets towards ORF1 and E-gene  
116 according to the manufacturer's instructions.

117 Within seven days of virus inoculation using clinical sample material, culture supernatant was  
118 collected to perform rRT-PCR in order to confirm productive virus replication. RNA was isolated  
119 from 100 µL cell culture supernatant using the QIAcube HT instrument and QIAamp 96 Virus  
120 QIAcube HT Kit (Qiagen; Hilden, Germany) according to the manufacturer's instructions. SARS-  
121 CoV-2 RNA was analyzed by rRT- PCR using the Luna Universal One-Step RT-qPCR Kit (New  
122 England Biolabs; Ipswich, Massachusetts, USA) and primers targeting RNA-dependent RNA  
123 polymerase (RdRp) [15]. RdRP\_SARSr-F2 (GTGARATGGTCATGTGTGGCGG)  
124 RdRP\_SARSr-R1 (CARATGTTAAASACACTATTAGCATA).

125

## 126 *2.6 Statistical Analysis*

127 The number of positive samples were compared two by two contingency table. The agreement  
128 between the antigen test and rRT-PCR techniques was evaluated using the Cohen's weighted  
129 kappa index (K value) [16]. K value interpretations were categorized as follows: <0.20 is poor,  
130 0.21- 0.40 is fair, 0.41-0.60 is moderate agreement, 0.61- 0.80 is substantial agreement and 0.81-  
131 1.00 is almost perfect agreement [17].


132 **2.7 Ethical Statement**

133 The use of stored clinical samples for validation of diagnostic methods without person related data  
134 is covered by section 25 of the Berlin hospital law and does not require ethical or legal clearance.  
135 The use of anonymized clinical samples for validation of diagnostic methods does not require  
136 ethical clearance by the Goethe University, Frankfurt.

137

138 **3. RESULTS**

139 Rapid antigen test sensitivity and specificity were evaluated by two independent institutions  
140 using various number of clinical samples. rRT-PCR was used as a reference test system. We  
141 deemed individuals to be uninfected with SARS-CoV-2 when a negative result was obtained by  
142 rRT-PCR.



143

144 **Figure 1. Antigen test analysis performed in Berlin (A) and Frankfurt (B).** A. Log<sub>10</sub> RNA  
145 copies/ml and corresponding antigen (Ag) detection test results (red circles positive n: 45, blue  
146 circles negative n: 13) intensity for each rRT-PCR positive sample (n: 58). B. Cycle threshold (cT)  
147 value and corresponding antigen (Ag) detection test results (red circles positive n: 16, blue circles  
148 negative n: 16) intensity for each rRT-PCR positive sample (n: 32). 32 rRT-PCR positive samples  
149 were tested in cell culture for infectivity. All Ag-test positive (n:16, red circles) and three Ag-test  
150 negative (red-filled blue circles) samples displayed CPEs after inoculating in Caco-2 cells (**Table**  
151 **S2**). Intensities of the test bands were compared to control band and designated as follows: +++

152 (test band intensity stronger than the control), ++ (test and control bands intensity are similar), +  
153 (test band intensity is weaker than the control).

154 In the Institute of Virology, Charité, Berlin, a total of 67 stored patient samples were  
155 available for the study. Of these, 58 were rRT-PCR positive with cycle threshold (cT) range  
156 between 18.77-40 corresponding to  $2.5 \times 10^9$  -1380 RNA genome copies/ml (**Table S1**),  
157 representing 86.6% (58/67) of the clinical samples analyzed (**Figure 1A**). When the rRT-PCR  
158 results were used as a reference, the antigen test diagnosed SARS-CoV-2 infection status with a  
159 sensitivity of 77.6% (45/58) and a specificity of 100% (9/9) (**Table 1**). After re-evaluating the data  
160 based on the acceptable analytic sensitivity and limit of detection suggested by WHO [18], we  
161 identified 48 samples with  $\geq 10^6$  RNA genome copies/ml. Rapid antigen test performed with 89.6%  
162 sensitivity for this sample set (**Table S1**). Of these, 40 samples had  $\sim 2.23 \times 10^6$  or more RNA  
163 genome copies/ml and reacted positive with the antigen test (**Table 1**). In contrast samples with  
164 less than  $7.63 \times 10^5$  RNA copies/ml were negative (**Figure 1A, Table S1**). Cohen's weighted kappa  
165 value of 0.482 indicated moderate agreement between the rRT-PCR and the rapid antigen test  
166 (**Table 2**). The overall concordance between the rRT-PCR and the antigen test was 80.6% (54/67).

167

		Antigen test				
		Negative	Positive	Marginal row	Sensitivity (%)	Specificity (%)
rRT-PCR	Negative	9	0	9		100
	Positive	13	45	58	77.6	
genome copies/ml	$\geq 2.23 \times 10^6$	0	40	40	100	
	$1.38 \times 10^3$ - $2.21 \times 10^6$	13	5	18	27.7%	

168

169 **Table 1.** Sensitivity and specificity of the antigen detection test in comparison to rRT-PCR

170

171



	Antigen test		
rRT-PCR	Negative	Positive	Row marginal
Negative	9	0	9 (13.4%)
Positive	13	45	58 (86.5%)
Column marginal	22 (32.8%)	45 (67.2%)	67

Weighted Kappa	0.482
Standard error	0.110
95% CI	0.266 to 0.698

172

173 **Table 2.** Cohen's weighted kappa coefficient between rapid antigen test and rRT-PCR.

174 Certain rapid tests may be used at the point-of-care and thus offer benefits for the detection  
175 and management of infectious diseases. In order to assess the potential of the rapid antigen test  
176 in this context, 70 nasopharyngeal samples freshly collected from individuals living in a shared  
177 housing were analyzed head to head by rRT-PCR using Cobas 6800 system, rapid antigen test,  
178 and cell culture using Caco-2 cells to determine the infectivity (Institute of Medical Virology,  
179 Goethe University, Frankfurt). 45.7% (32/70) of the clinical samples were diagnosed positive for  
180 SARS-CoV-2 by rRT-PCR with cT values ranging between 18.01-35.98 (**Figure 1B, Table S2**).  
181 The antigen test diagnosed the infection status with a sensitivity of 50% (16/32) and a specificity  
182 of 100% (**Table 3**). Re-evaluating the data based on the limit of detection, sensitivity was  
183 determined to be 88.2% for samples with cT values <28, and it was reduced in the group of  
184 samples with cT values  $\geq 28$  (6.7%) (**Table 3**). Cohen's weighted kappa value of 0.521 indicated  
185 moderate agreement between rRT-PCR and the rapid antigen test (**Table 4**). The overall  
186 concordance between the rRT-PCR and the antigen test was 77.1% (54/70) (**Table 4**).

187 rRT-PCR is a highly sensitive method to detect viral RNA molecules from clinical samples.  
188 However, viral RNA can persist in different body parts and can be detected in specimens for much  
189 longer than the presence of viable virus [19]. Thus demonstration of infectivity on permissive cell  
190 lines *in vitro* is a more reliable surrogate for infectivity and virus transmission. Therefore, we

191 attempted virus isolation by inoculating rRT-PCR positive samples in Caco-2 cells. Cytopathic  
 192 changes were monitored daily by microscopy for a week and subsequently aliquots of culture  
 193 supernatant were tested to verify viral RNA copies (**Table S2**). For samples that are positive for  
 194 both antigen test and rRT-PCR (16/32, cT 18.01-28.45), we observed cytopathic effects (CPE) in  
 195 cell culture 1-3 days after inoculation (**Figure 1B, Table S2**). Three samples that had a negative  
 196 result in the antigen test, but were positive by rRT-PCR (cT values 26.69, 30.12, and 32.13)  
 197 displayed CPE as well. Other 13 antigen-test negative samples with higher cT values (indicating  
 198 lower viral load) between 28.34-34.12 were not infectious in cell culture. Interestingly, one sample  
 199 with a relatively low cT value 25.53, did not show any CPE in cell culture and was also negative  
 200 for the antigen test (**Table S2**).

201

		Antigen test				
		Negative	Positive	Marginal row	Sensitivity (%)	Specificity (%)
rRT-PCR	Negative	38	0	38		100
	Positive	16	16	32	50	
cT<28	Positive	2	15	17	88.2	
cT≥28	Positive	14	1	15	6.7	

202

203 **Table 3.** Comparison of the clinical diagnostic performance of rapid antigen test with rRT-PCR.

204

	Antigen test		
rRT-PCR	Negative	Positive	Row marginal
Negative	38	0	38 (54.3%)
Positive	16	16	32 (45.7%)
Column marginal	54 (77.1%)	16 (22.9%)	70

Weighed Kappa	0.521
Standard error	0.092
95% CI	0.339 to 0.702

205

206 **Table 4.** Cohen’s weighted kappa coefficient between rapid antigen test and rRT-PCR.

207 In order to investigate potential cross reactivity among common coronaviruses and other  
208 respiratory viruses, infectious and heat inactivated (4 h at 60°C) cell culture supernatants were  
209 tested (**Table 5**). SARS-CoV-1 and SARS-CoV-2 tested positive with the antigen test, as  
210 expected. The antigen test did not display any cross-reactivity with the other respiratory and  
211 endemic corona viruses listed in **Table 5**.

212


Cell culture supernatant with virus	Ag-Test
SARS-CoV-1	+
SARS-CoV-2	+
HCoV-229E	-
HCoV-NL63	-
MERS	-
Enterovirus	-
Rhinovirus	-
Parainfluenzavirus 1	-
Parainfluenzavirus 2	-
Parainfluenzavirus 3	-
Parainfluenzavirus 4	-
hMPV A	-
hMPV B	-
RSV	-
Influenzavirus A H1N1	-
Influenzavirus A H3N2	-
Influenza B	-

213

214 **Table 5.** Rapid Antigen Test results using different respiratory virus cell culture supernatant  
215 stocks.

216 We further evaluated the detection sensitivity among different SARS-CoV-2 isolates. Here  
217 we used cell culture supernatant collected from Caco-2 cells infected with seven different isolates  
218 [15] and SARS-CoV-1 (**Figure 3**). The virus stocks were thawed at room temperature and a total

219 of six 10-fold dilutions were prepared in PBS. The antigen test was performed and evaluated  
220 immediately (**Figure 3A**). In parallel, aliquots of the dilutions were mixed with lysis buffer used for  
221 RNA extraction to inactivate the virus. rRT-PCR was performed for two different gene targets  
222 ORF1 and E-gene that resulted in similar cT values (**Figure 3B, Table S3**). 10-fold serial dilutions  
223 led to ~3 cT difference in rRT-PCR for each set as anticipated. According to our results the limit  
224 of detection was between 100-560 RNA copies/ml which is in line with the manufacturer's findings.  
225 We previously identified RG203KR mutations in FFM3, FFM4 and FFM6 and S→L mutation in  
226 FFM1 within the nucleocapsid protein coding region [15]. According to GISAID classification the  
227 GR clade, carrying the combination of Spike D614G and nucleocapsid RG203KR mutations, is  
228 currently the most common representative of the SARS-CoV-2 population worldwide [20]. Our  
229 results suggest that the presence of the RG203KR mutation did not interfere with the antigen test  
230 performance.



231

232 **Figure 3.** Rapid Antigen Test Results for SARS-CoV-1 and SARS-CoV-2 isolates. **A.**  
233 Representative lateral flow assay using serially diluted virus stock. Intensities of the test bands  
234 were compared to control band and designated as follows: +++ (test band intensity stronger than  
235 the control), ++ (test and control bands intensity are similar), + (test band intensity is weaker than  
236 the control). **B.** TCID50/ml values and corresponding antigen (Ag) detection test intensity for  
237 serially diluted SARS-CoV-2 isolates FFM1-7 and SARS-CoV-1 are shown. Representative result  
238 of two experiments.

239

#### 240 4. DISCUSSION

241 In this study we validated the assay performance of a recently approved rapid antigen test  
242 in two independent institutions using a total of 137 clinical samples. Although the test specificity  
243 was 100% for this particular sample set, overall sensitivity was low (50-77.6%), yet re-analyzing  
244 samples with higher viral loads showed good correlation (88.2-89.6%). Previous studies reported  
245 that lower cT values are associated with higher viral culture positivity [21, 22]. There is currently  
246 no direct evidence whether cell culture positivity or higher viral load correlates with contagiousness  
247 of an individual, however, it is commonly recognized as the surrogate of infectivity [23]. Since an  
248 important aspect of using point-of-care testing is to able to identify infected individuals who are  
249 infectious and can potentially transmit the virus, we performed correlation analysis within a group  
250 of clinical samples tested. 19 out of 32 SARS-CoV-2 infected individuals were positive in cell  
251 culture. The antigen test detected 16 out of 19 these (84%). In contrast 43.7% (14/32) of the  
252 samples were not infectious in cell culture, yet positive by rRT-PCR, probably due to persisting  
253 genomic and subgenomic viral RNA within the collected sample. We detected an excess amount  
254 of viral RNA in cell culture supernatants due to high replication capacity of the virus in permissive  
255 cells, despite a negative antigen test result. This might explain the cT discrepancy between the  
256 cell culture supernatant and clinical samples. Limited clinical sample size is the major limitation of  
257 this study. Future efforts should aim to monitor frequent sampling of larger groups and to compare  
258 different rapid antigen tests, different sampling sites along with infectivity correlation in cell culture.

259 Our results suggest that the rapid antigen test can detect SARS-CoV-2 infected individuals  
260 with high viral loads and has potential in determining highly contagious individuals. Despite low  
261 analytic sensitivity, rapid antigen tests are inexpensive and therefore can be used frequently for  
262 detecting infected individuals who are asymptomatic, pre-symptomatic and without known or  
263 suspected exposure to SARS-CoV-2 [24]. They can be beneficial in congregate settings, such as  
264 a long-term care facility or a correctional facility, workplace, or a school testing its students, faculty,

265 and staff. Rapid antigen tests probably perform best during the early stages of SARS-CoV-2

266 infection when the viral load is higher.

267

268 **ACKNOWLEDGMENTS**

269 Parts of this work was funded by the German Ministry of Health (Konsiliarlabor für Coronaviren)  
270 to C.D. and V.M.C. and by the German Ministry of Research through projects VARIPath  
271 (01KI2021) to V.M.C.

272 This project was funded in part by the German Federal Ministry of Education and Research  
273 (Bundesministerium für Bildung und Forschung, BMBF) (NaFoUniMedCovid19 – B-FAST,  
274 EVIPAN, FKZ: 01KX2021).

275 We thank Lara Jeworowski and Tobias Bleicker for their assistance, Felix Drexler for providing  
276 heat inactivated respiratory viruses for specificity testing, Dr. Holger Rabenau for organizational  
277 support, Marhild Kortenbusch and Regine Jeck for technical assistance.

278

279

280 **SUPPLEMENTARY TABLES**

281 **Table S1.** Summary of rRT-PCR and antigen testing using clinical samples (Charite, Berlin). neg:

282 negative antigen test. N/D: not detectable.

283

Sample ID	rRT-PCR		Antigen test
	E-gene	Log10 RNA copies/mL	Intensity
#65	18,77	9,40	+++
#19	19,48	9,18	+++
#60	20,02	9,01	+++
#56	20,72	8,80	+++
#22	21,78	8,47	+++
#66	22,01	8,40	+++
#25	22,02	8,40	+++
#67	22,16	8,35	++
#21	22,74	8,17	+++
#20	22,94	8,11	+++
#57	23,11	8,06	++
#15	23,19	8,04	+++
#53	24,07	7,76	+++
#26	24,15	7,74	+++
#8	24,24	7,71	++
#12	25,15	7,43	++
#27	25,47	7,33	+
#58	25,7	7,26	+
#14	25,74	7,25	++
#1	25,92	7,19	++
#18	26,04	7,16	++
#64	26,12	7,13	+++
#4	26,14	7,13	+++
#10	26,22	7,10	++
#11	26,44	7,03	++
#23	26,71	6,95	++
#3	26,81	6,92	+++
#28	26,89	6,90	++
#29	26,89	6,90	++
#61	26,98	6,87	+++
#5	27,03	6,85	+
#13	27,05	6,85	++



#59	27,09	6,83	+
#55	27,32	6,76	+
#49	27,47	6,72	+
#2	27,69	6,65	++
#17	27,85	6,60	++
#6	28,49	6,40	++
#7	28,52	6,39	++
#9	28,67	6,35	+
#46	28,68	6,34	neg
#50	28,92	6,27	neg
#51	29,21	6,18	+
#47	29,36	6,14	neg
#24	29,46	6,10	+
#32	29,59	6,06	+
#33	29,64	6,05	neg
#31	29,68	6,04	neg
#16	29,83	5,99	+
#54	29,87	5,98	+
#52	30,18	5,88	neg
#48	30,81	5,69	neg
#30	31,45	5,49	neg
#39	33,13	4,97	neg
#43	33,61	4,83	neg
#62	35,76	4,16	neg
#63	35,98	4,10	neg
#41	40	3,14	neg
#34	N/D	N/D	neg
#35	N/D	N/D	neg
#36	N/D	N/D	neg
#37	N/D	N/D	neg
#38	N/D	N/D	neg
#40	N/D	N/D	neg
#42	N/D	N/D	neg
#44	N/D	N/D	neg
#45	N/D	N/D	neg

284

285

286

287 **Table S2.** Summary of rRT-PCR (Cobas), antigen testing, virus isolation in cell culture, rRT-PCR  
 288 with cell culture supernatant of 70 clinical samples (University Hospital Frankfurt). neg: negative  
 289 antigen test. N/D: not detectable.

Sample ID	Roche (COBAS) rRT-PCR		Antigen test	CPE in cell culture	Luna One-step RdRP rRT-PCR with culture supernatant
	ORF1	E-gene			
1	18,01	18,01	+++	+	20,67
2	20,22	20,42	+++	+	21,27
3	21,45	21,31	++	+	20,69
4	21,9	20,97	+	+	19,89
5	21,96	22,27	+++	+	19,66
6	22,2	22,39	+	+	20,72
7	23,31	23,33	+	+	20,68
8	23,33	23,21	++	+	20,41
9	23,51	23,1	+	+	20,64
10	23,76	23,7	+	+	20,22
11	24,91	25,4	++	+	20,99
12	25,3	25,53	neg	-	36,72
13	26,4	26,63	+	+	20,93
14	26,56	26,69	neg	+	20,32
15	26,91	26,2	+	+	20,74
16	27,04	27,01	+	+	20,31
17	27,46	27,11	+	+	20,23
18	27,78	28,45	+	+	21,16
19	28,39	28,92	neg	-	36,11
20	28,8	28,34	neg	-	40,18
21	29,32	30,12	neg	+	20,64
22	29,84	30,54	neg	-	38,55
23	30,15	31,03	neg	-	41,26
24	30,45	31,35	neg	-	37,28
25	31,49	32,77	neg	-	36,69
26	31,89	32,99	neg	-	37,30
27	32,19	33,06	neg	-	37,39
28	32,34	34,03	neg	-	36,73
29	33,69	32,13	neg	+	20,50
30	35,01	33,04	neg	-	38,44
31	35,39	33,67	neg	-	39,52
32	35,78	34,12	neg	-	36,94
33	36,3	N/D	neg	-	36,68
34	N/D	N/D	neg		
35	N/D	N/D	neg		
36	N/D	N/D	neg		
37	N/D	N/D	neg		
38	N/D	N/D	neg		
39	N/D	N/D	neg		
40	N/D	N/D	neg		
41	N/D	N/D	neg		
42	N/D	N/D	neg		
43	N/D	N/D	neg		
44	N/D	N/D	neg		
45	N/D	N/D	neg		
46	N/D	N/D	neg		
47	N/D	N/D	neg		
48	N/D	N/D	neg		

49	N/D	N/D	neg
50	N/D	N/D	neg
51	N/D	N/D	neg
52	N/D	N/D	neg
53	N/D	N/D	neg
54	N/D	N/D	neg
55	N/D	N/D	neg
56	N/D	N/D	neg
57	N/D	N/D	neg
58	N/D	N/D	neg
59	N/D	N/D	neg
60	N/D	N/D	neg
61	N/D	N/D	neg
62	N/D	N/D	neg
63	N/D	N/D	neg
64	N/D	N/D	neg
65	N/D	N/D	neg
66	N/D	N/D	neg
67	N/D	N/D	neg
68	N/D	N/D	neg
69	N/D	N/D	neg
70	N/D	N/D	neg

290

291

292

293 **Table S3.** Cycle threshold (cT) value for ORF1 and E-gene rRT-PCR and rapid antigen test results  
 294 for serially diluted SARS-CoV-2 isolates and SARS-CoV-1. neg: negative antigen test.

295

SAMPLE	TCID50/ml	rRT-PCR (Cobas)		Ag-Test
		ORF1	E-gene	Intensity
SARS-CoV-2 FFM1	1,3E+05	13,12	13,86	+++
	1,3E+04	16,56	16,79	+++
	1,3E+03	20,22	20,52	++
	1,3E+02	23,86	24,10	+
	1,3E+01	27,24	27,63	neg
	1,3E+00	30,50	31,02	neg
SARS-CoV-2 FFM2	1,0E+05	20,12	20,37	+++
	1,0E+04	23,23	23,62	++
	1,0E+03	27,07	27,29	+
	1,0E+02	30,25	30,53	neg
	1,0E+01	33,24	33,83	neg
	1,0E+00	34,78	36,23	neg
SARS-CoV-2 FFM3	1,0E+05	16,36	16,63	+++
	1,0E+04	19,78	19,95	+++
	1,0E+03	23,45	23,54	+
	1,0E+02	26,72	27,14	neg
	1,0E+01	30,15	30,68	neg
	1,0E+00	33,17	33,87	neg
SARS-CoV-2 FFM4	5,6E+05	12,7	13,4	+++
	5,6E+04	16,3	16,78	+++
	5,6E+03	19,46	19,73	+++
	5,6E+02	23,3	23,5	+
	5,6E+01	26,61	26,93	neg
	5,6E+00	29,7	30	neg
SARS-CoV-2 FFM5	1,0E+05	13,96	14,08	+++
	1,0E+04	16,66	16,81	+++
	1,0E+03	20,13	20,33	+++
	1,0E+02	23,26	23,64	++
	1,0E+01	27,01	27,08	+
	1,0E+00	29,74	30,11	neg
SARS-CoV-2 FFM6	1,0E+05	16,1	16,35	+++
	1,0E+04	19,57	19,83	+++
	1,0E+03	23,43	23,47	++
	1,0E+02	26,36	26,63	+
	1,0E+01	30,04	30,64	neg
	1,0E+00	33,36	34,05	neg
SARS-CoV-2 FFM7	3,0E+05	14,87	15,12	+++
	3,0E+04	17,71	18,02	+++
	3,0E+03	21,95	22,4	++
	3,0E+02	25,4	26,12	+
	3,0E+01	28,81	29,26	neg
	3,0E+00	32,11	32,72	neg
SARS-CoV-1	1,0E+05	n/d	17	+++
	1,0E+04	n/d	20,2	++
	1,0E+03	n/d	24,54	+
	1,0E+02	n/d	27,71	neg
	1,0E+01	n/d	31,1	neg
	1,0E+00	n/d	34,21	neg

296

297 **REFERENCES**

- 298 [1] Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019  
299 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill.* 2020;25.  
300 [2] WHO WHO. Laboratory testing for coronavirus disease (COVID-19) in suspected human  
301 cases. Interim guidance 2020. 2020.  
302 [3] CDC C-NC-nR-TR-PDP. CDC, CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-  
303 PCR Diagnostic Panel 2020.  
304 [4] FIND FfIND. Sars-Cov-2 Diagnostic Pipeline. 2020.  
305 [5] Matheeußen V, Corman VM, Donoso Mantke O, McCulloch E, Lammens C, Goossens H, et  
306 al. International external quality assessment for SARS-CoV-2 molecular detection and survey on  
307 clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020. *Euro Surveill.*  
308 2020;25.  
309 [6] van Kasteren PB, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den Brandt A,  
310 et al. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. *J Clin Virol.*  
311 2020;128:104412.  
312 [7] Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types  
313 of Clinical Specimens. *JAMA.* 2020;323:1843-4.  
314 [8] Mohammadi A, Esmaeilzadeh E, Li Y, Bosch RJ, Li JZ. SARS-CoV-2 detection in different  
315 respiratory sites: A systematic review and meta-analysis. *EBioMedicine.* 2020;59:102903.  
316 [9] Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA.*  
317 2020;323:2249-51.  
318 [10] Porte L, Legarraga P, Vollrath V, Aguilera X, Munita JM, Araos R, et al. Evaluation of a novel  
319 antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples. *Int J*  
320 *Infect Dis.* 2020;99:328-33.  
321 [11] Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, et al. Clinical Evaluation  
322 of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR,  
323 Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To  
324 Diagnose COVID-19. *J Clin Microbiol.* 2020;58.  
325 [12] Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, et al. Comparison  
326 of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using  
327 313 nasopharyngeal swabs, including from seven serially followed patients. *Int J Infect Dis.*  
328 2020;99:397-402.  
329 [13] Lindner AK, Nikolai O, Kausch F, Wintel M, Hommes F, Gertler M, et al. Head-to-head  
330 comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected anterior nasal swab  
331 versus professional-collected nasopharyngeal swab. *medRxiv.* 2020:2020.10.26.20219600.  
332 [14] Krüger LJ, Gaeddert M, Köppel L, Brümmer LE, Gottschalk C, Miranda IB, et al. Evaluation  
333 of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care  
334 diagnostics for SARS-CoV-2. *medRxiv.* 2020:2020.10.01.20203836.  
335 [15] Toptan T, Hoehl S, Westhaus S, Bojkova D, Berger A, Rotter B, et al. Optimized qRT-PCR  
336 Approach for the Detection of Intra- and Extra-Cellular SARS-CoV-2 RNAs. *Int J Mol Sci.* 2020;21.  
337 [16] Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement  
338 or partial credit. *Psychological bulletin.* 1968;70:213-20.  
339 [17] Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics.*  
340 1977;33:159-74.  
341 [18] WHO WHO. Target product profiles for priority diagnostics to support response to the COVID-  
342 19 pandemic v.1.0. 2020.  
343 [19] Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological  
344 assessment of hospitalized patients with COVID-2019. *Nature.* 2020;581:465-9.  
345 [20] Mercatelli D, Giorgi FM. Geographic and Genomic Distribution of SARS-CoV-2 Mutations.  
346 *Front Microbiol.* 2020;11:1800.

- 347 [21] Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting infectious  
348 SARS-CoV-2 from diagnostic samples. *Clin Infect Dis*. 2020.
- 349 [22] La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA  
350 load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients  
351 from infectious disease wards. *European journal of clinical microbiology & infectious diseases* :  
352 official publication of the European Society of Clinical Microbiology. 2020;39:1059-61.
- 353 [23] Jefferson T, Spencer E, Brassey J, Heneghan C. Viral cultures for COVID-19 infectivity  
354 assessment. *Systematic review*. medRxiv. 2020:2020.08.04.20167932.
- 355 [24] Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for  
356 Containment. *N Engl J Med*. 2020.

357